• Adrian Simpson, United States says, "If you are looking for a fair deal on medical supplies, IDM is something I would seriously recommend. Am hooked for life."
  • Craig, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "IDM makes online shopping a pleasure. Shopping is so simple that you just breeze through it."
  • Harry Mason, United States says, "I have to admit am a bit of a lazy bloke when it comes to ordering online .And IDM pampers me to the hit as it's so simple to order."
  • John Hanks, United States says, "I was a sceptic until my first order. After, I received my first package, I turned believer. Now, it’s been 3 years since I have been ordering from IDM."
  • Natalie Wallace, United States says, "I was apprehensive about how my doubts would be addressed but what the heck,I went ahead and placed my order. Customer service was patient and helped me out."
  • Mark Penning, United States says, "Happy I got my package just in time for my vacation. Needless to say, it made my holiday a wonderfully satisfying experience."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy
    Follow us on Twitter

      Ranbaxy targets M&A for drugs growth

      Ranbaxy Laboratories Ltd is actively pursuing a handful of acquisition opportunities in the United States and elsewhere to boost its generics drugs business, its new CEO said on Wednesday.

      Malvinder Singh, who took over the job at India's leading drugmaker last week, said he hoped a deal might be clinched in 2006, adding the U.S. market was a key priority.

      "We are actively looking at some targets today. My intent would be to look at concluding something (this year), but it must be a strategic fit that adds value," he told Reuters on the sidelines of the World Economic Forum annual meeting in Davos.

      "Clearly, in America we need to gain critical size," the chief executive added.

      "Our U.S. business today is around $350 million (a year). I think it is quite feasible to look at the same size through acquisition." Ranbaxy, which had worldwide sales of $1.2 billion in 2005, has ambitions to reach $2 billion in 2007 and then $5 billion by 2012 to become one of the world's top five generic drug companies.

      The generic drugs industry has seen a wave of consolidation recently, spearheaded by market leaders Teva Pharmaceutical Industries Ltd and Sandoz, the generics arm of Novartis AG.

      Singh noted that generic drugs businesses had sold in the past year for between one and five times their annual sales.

      Around the world, cheap generic medicines are in a sweet spot as governments promote their use to cut costs and as more branded blockbuster drugs lose patent protection.

      But competition is fierce, leading to pressure on prices and encouraging companies to seek greater economies of scale.

      That took a heavy toll on Ranbaxy in 2005, when profits fell 63 per cent and its shares lost 42 per cent due to falling prices in the United States, patent battle setbacks and high legal and research costs.

      January 25, 2006


       

      Share this Article!

    Back to top^